Journal Browser

Journal Browser

Special Issue "New Beta-Lactams, Beta-Lactamase Inhibitors and Targets for Beta-Lactamase Production Blockade: Powerful Allies against Multidrug-Resistant Pathogens 2.0"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editor

Dr. Carlos Juan Nicolau
E-Mail Website
Guest Editor
Hospital Universitari Son Espases- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
Interests: nosocomial gram-negative pathogens; antibiotic resistance; peptidoglycan biology; host-pathogen interaction; virulence; cell-wall-targeting immunity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Antibiotic resistance, especially referred to nosocomial opportunistic bacterial pathogens, is already an undeniable threat for public health worldwide, with obvious clinical and economic consequences. In the specific context of beta-lactam antibiotics, the threat is certainly not less severe, given their generalized use. Nevertheless, the appearance of new therapeutic options brings us a reason for hope. Among these therapeutic allies, we acknowledge: (i) the appearance of novel beta-lactam-related drugs (such as cefiderocol or ceftobiprole); (ii) the use of new antibiotic combinations including beta-lactamase activity inhibitors (for instance ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, and meropenem-vaborbactam), and (iii) the research on unexplored targets leading to the blockade of intrinsic beta-lactamases production (usually related to cell wall metabolism, such as AmpG or NagZ proteins, which have been shown to be essential for the correct expression of intrinsic beta-lactamases and full virulence in Pseudomonas aeruginosa and related species). Reviews and research papers related to these topics (referring to either Gram-positive or Gram-negative pathogens), but also those about novel characterizations of acquired/intrinsic Beta-lactamases are welcome for this Special Issue.

Dr. Carlos Juan Nicolau
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.



  • Antibiotic resistance
  • ESKAPE pathogens
  • MRSA
  • Enterobacteriaceae
  • Acinetobacter baumannii
  • Pseudomonas aeruginosa
  • horizontally acquired beta-lactamases
  • carbapenemases
  • beta-lactamase inhibitors
  • intrinsic beta-lactamases
  • peptidoglycan recycling
  • cell wall metabolism
  • virulence
  • AmpC cephalosporinase
  • Cefiderocol
  • Ceftobiprole
  • ceftazidime/avibactam
  • ceftolozane/tazobactam
  • imipenem/relebactam
  • meropenem/vaborbactam

Related Special Issue

Published Papers

This special issue is now open for submission.
Back to TopTop